A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants

Diabetes Care. 2011 Nov;34(11):2435-7. doi: 10.2337/dc11-0981. Epub 2011 Sep 12.

Abstract

Objective: We examined changes in GAD65 and ICA-512 autoantibodies (GADA and IA-2A) during progression to type 1 diabetes (T1D).

Research design and methods: Diabetes Prevention Trial-Type 1 (DPT-1) participants were assessed for changes in positivity and titers of GADA and IA-2A during the progression to T1D.

Results: Among 99 progressors to T1D with GADA and IA-2A measurements at baseline and diagnosis (mean interval = 3.3 ± 1.5 years), GADA positivity changed little and GADA titers decreased (P < 0.01). In contrast, both IA-2A positivity and titers increased substantially (P < 0.001). Even among those positive at baseline, IA-2A titers increased from baseline to diagnosis (n = 57; P < 0.001), whereas GADA titers decreased (n = 80; P < 0.01). The same patterns of change were also evident among those positive for both autoantibodies (n = 48) at baseline.

Conclusions: IA-2A titers increase during the years before the diagnosis of T1D, even among those positive for IA-2A. In contrast, GADA titers tend to decline during those years.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Autoantibodies / blood
  • Autoantibodies / immunology
  • Autoantibodies / metabolism*
  • Child
  • Child, Preschool
  • Diabetes Mellitus, Type 1 / immunology*
  • Disease Progression
  • Female
  • Glucose Tolerance Test
  • Glutamate Decarboxylase / immunology
  • Glutamate Decarboxylase / metabolism*
  • Humans
  • Islets of Langerhans / immunology
  • Longitudinal Studies
  • Male
  • Young Adult

Substances

  • Autoantibodies
  • ICA512 autoantibody
  • Glutamate Decarboxylase
  • glutamate decarboxylase 1